Deprivation Tied to Lower HNC-Specific QOL - Report - MDSpire

Deprivation Tied to Lower HNC-Specific QOL

  • By

  • Andrea Surnit

  • June 22, 2026

  • 5 min

Share

Clinical Report: Deprivation Tied to Lower HNC-Specific QOL

Overview

Patients with head and neck cancer from socioeconomically disadvantaged neighborhoods reported significantly lower pretreatment quality-of-life scores compared to those from less disadvantaged areas.

Background

Understanding the relationship between socioeconomic factors and quality of life (QOL) in head and neck cancer patients is crucial for addressing disparities in care. This study provides insights into how neighborhood deprivation may affect QOL even before treatment begins.

Data Highlights

MeasureScore
Mean age of cohort62.5 years
Percentage of male patients72%
Percentage with stage III to IV disease52%
Mean FACT-HN score27.7
Adjusted difference in QOL scores (most vs least disadvantaged)−3.62 points (95% CI: −6.23 to −1.01)

Key Findings

  • Patients in the most disadvantaged neighborhoods had lower head and neck cancer-specific well-being scores compared to those in the least disadvantaged neighborhoods.
  • The adjusted difference in scores was −3.62 points, indicating a significant disparity.
  • Unadjusted analyses showed that greater neighborhood disadvantage was linked to lower ability to eat preferred foods and swallow easily.
  • Patients from more disadvantaged areas reported higher tobacco product use.
  • The study's cross-sectional design limits the ability to infer causation between neighborhood deprivation and QOL.
  • Findings may not be generalizable due to the single-institution study design and demographic limitations.

Clinical Implications

Healthcare providers should consider the socioeconomic context of patients when assessing quality of life in head and neck cancer. Understanding these disparities may help in tailoring supportive care and interventions to improve patient outcomes.

Conclusion

The study reveals significant associations between neighborhood socioeconomic status and quality of life in head and neck cancer patients.

Related Resources & Content

  1. JAMA Otolaryngology–Head & Neck Surgery, 2023 -- Patient-Reported Quality of Life and Socioeconomic Disadvantage Among Patients With Head and Neck Cancer
  2. JAMA Network Open, 2025 -- Neighborhood Deprivation and Biological and Psychosocial Outcomes for Head and Neck Cancer
  3. PMC, 2023 -- Deprivation Indices in Head and Neck Cancer: A Scoping Review
  4. Journal of Neuro-Oncology — Psychosocial Well-Being and Influencing Factors on Health-Related Quality of Life in Children with Neurofibromatosis Type 1 and Cognitive Challenges
  5. Frontiers in Neurology — Quality of Life and Its Influencing Factors in Patients with neuromyelitis optica spectrum disorder
  6. Frontiers in Neurology — Physical disability, cognition, and depression as determinants of quality of life in multiple sclerosis: a cross-sectional study
  7. Impact of Post-Surgical Hypoparathyroidism on Quality of Life Following Thyroid and Parathyroid Operations
  8. What the newest evidence shows about deprivation and pretreatment QOL in HNC
  9. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025
  10. Neighborhood Deprivation and Biological and Psychosocial Outcomes for Head and Neck Cancer | Oncology | JAMA Network Open | JAMA Network
  11. Deprivation Indices in Head and Neck Cancer: A Scoping Review - PMC
  12. Oropharyngeal Cancer Treatment (PDQ®) - NCI
  13. Social Determinants of Health and Cancer Care: An ASCO Policy Statement | JCO Oncology Practice
  14. Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer – Results from NRG/RTOG 1016 - PMC
  15. Intensity-modulated radiation therapy (IMRT) matches proton therapy in patient-reported outcomes for oropharyngeal cancer - American Society for Radiation Oncology (ASTRO)
  16. Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma

Original Source(s)

Related Content